News about BigHat

November 18, 2020

Peyton Greenside, BigHat CSO, speaks about machine-guided biological design

BigHat Biosciences co-founder and CSO Peyton Greenside spoke with Anika Gupta on her podcast The Data Pulse about machine-guided biological design. A great opportunity to learn more about how BigHat applies active learning to antibody engineering.

October 1, 2020

BigHat Biosciences earns Phase I award from NIST to show power of AI-driven platform

BigHat Biosciences received a Phase I SBIR award from NIST (National Institute of Standards and Technology) to apply its AI-driven platform to rapidly identify high-yield expression vectors for therapeutic antibody production.

BigHat’s Chief Scientific Officer, Dr. Peyton Greenside, noted, “We are honored that NIST sees the potential for our approach. This Phase I study will demonstrate that BigHat’s platform can design novel and improved DNA templates by querying only a tiny fraction of candidate sequences in a massive search space.”

The Phase I SBIR grant aims to increase protein production by jointly optimizing a 30 base pair DNA sequence involving the expression cassette and start of the protein coding sequence through tight coupling of computational and experimental evaluation on the BigHat platform. Sequences longer than ~10 base pairs have been historically intractable to search effectively because the search space is simply too large for comprehensive experimental exploration.

“We started BigHat Biosciences because we believe that AI/ML-powered molecular engineering will allow us to design biotherapeutics inaccessible to traditional approaches,” shared CEO Mark DePristo, PhD. “Our work with NIST will help BigHat benchmark and further improve our technologies for data-driven antibody design.


About BigHat Biosciences

BigHat Biosciences is an early-stage Bay Area startup reimagining antibody discovery and engineering to create better antibodies faster and undertake novel designs far beyond what's possible today. BigHat designs antibodies using an agile, multi-objective, and data-driven platform that integrates a high-speed wet lab with AI and machine learning. Founded in 2019, BigHat Biosciences counts among its founders, employees, and advisors world-leading experts in machine learning and artificial intelligence, computational biology, software engineering, and drug development. BigHat’s investors include 8VC, AME Cloud Ventures, and Innovation Endeavors. Learn more at www.bighatbio.com.

About NIST

NIST (National Institute of Standards and Technology), a nonregulatory agency of the U.S. Department of Commerce, promotes U.S. innovation and industrial competitiveness by advancing measurement science, standards and technology in ways that enhance economic security and improve our quality of life. To learn more about NIST, visit NIST.gov.

September 15, 2020

BigHat awarded 2020 Golden Ticket from Amgen and MBC Biolabs

Amgen and MBC BioLabs announced today that BigHat Biosciences has been awarded a 2020 Amgen Golden Ticket to MBC BioLabs.

BigHat was chosen by a team of scientific leaders who evaluated the strength and novelty of our scientific rationale, subject matter expertise, and business plan viability.

Flavius Martin, vice president of Oncology, Inflammation and Site Head at Amgen South San Francisco, said "BigHat Biosciences [...] is working on promising early-stage innovation that address serious illnesses such as cancer, autoimmune diseases, infectious diseases, and others [...] We are happy to support their scientific efforts as they tackle complex research challenges that potentially address critical unmet medical needs for patients. Congratulations to both companies and their scientific entrepreneurs.”

BigHat will use Amgen's support for our facility at MBC BioLabs and access to their biologics R&D group to help accelerate its mission to radically improve antibody design using the latest techniques in machine learning and synthetic biology.

BigHat joins Golden Ticket winners Trilo Therapeutics (2020), Regencor and Nitrome Biosciences (2019), Delve Therapeutics and Mitokinin (2018), Darmiyan and Enable Biosciences (2017), and Mission Bio and SiteOne Therapeutics.

August 12, 2020

BigHat founder discusses COVID-19's impact on early-stage startups

BigHat co-founder Peyton Greenside joins a panel discussion, along other leaders from Silicon Valley Bank, Civilization Ventures, Pivotal Bioventure Partners, BioRock Ventures, to discuss: Is this The Lost Year for Startups, or the Year of Greatest Opportunity?

2020 has brought renewed focus to the promise of biotech and the ability of novel therapeutics to meet society's urgent needs. It has also highlighted the current limits of science, the fragility of our health care system, and the long process from R&D to market for new drugs. What does this all mean for you and your startup, and how will you thrive amidst the uncertainty? Our expert VC/CEO panelists weigh in with concrete advice and stories from the trenches.

July 18, 2020

BigHat founder presents active learning innovations at ICML 2020

​BigHat founder Peyton Greenside and BigHat consultant Vivek Myers presented their work A Hierarchical Approach to Scaling Batch Active Search Over Structured Data at the ICML Workshop on Real World Experiment Design and Active Learning. The method enables efficient, large-batch search over a structured set of protein or DNA sequences by combining deep representation learning with a hierarchical search strategy. It balances broad exploration over unobserved sequence space with more greedy local search where promising sequences have been identified. These innovations were possible by taking advantage of the natural emergent structure in a large corpus of related biological sequences to help guide experimental design in a high-throughput setting.

June 9, 2020

BigHat founder speaks at the annual European Society for Human Genetics (ESHG) 2020 meeting

April 30, 2020

BigHat founder talks leading interdisciplinary teams with Stanford Accel Scholars

BigHat founder Peyton Greenside joins Insitro team member to lead working session with Stanford's Accel Innovation Scholars on building and leading interdisciplinary teams.

December 4, 2019

BigHat founder at the Cell Free Systems conference

​BigHat founder Peyton Greenside helps select the best poster at the Cell Free Systems Conference in Boston, MA.

November 11, 2019

BigHat founder moderates Deep Life salon

BigHat founder Peyton Greenside moderates Innovation Endeavors' Deep Life Salon panel between biotech founders and pharmaceutical partners from Novozymes and Novo Nordisk on commercializing research.

October 30, 2019

BigHat founder speaks at Open Data Science conference

October 22, 2019

BigHat closes oversubscribed seed round

BigHat announces the closing of its oversubscribed seed round, led by 8VC and joined by AME Cloud Ventures and Innovation Endeavors.